Novartis | NOVN - Коммерческие и административные расходы





Коммерческие и административные расходы Изменить Дата
AbbVie USD 3.63B 54M 2026-06
Alcon AG USD 882M 19M 2026-03
Amgen USD 1.72B 134M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Autolus Therapeutics Ltd USD 39.95M 4.16M 2026-03
Bayer EUR 3.96B 267M 2026-06
Biogen USD 709.7M 155.4M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Eli Lilly USD 3.43B 496M 2026-06
Fresenius EUR 760M 17M 2026-06
Fresenius Medical Care EUR 736.01M 12.99M 2026-06
Genmab DKK 205M 39M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
GRIFOLS EUR 289M 8M 2026-06
Hikma Pharmaceutical USD 288M 149M 2025-12
J&J USD 6.42B 381M 2026-06
Lakefront Biotherapeutics EUR 35.5M 8.91M 2026-03
Merck EUR 1.57B 49M 2026-06
Merck USD 2.89B 219M 2026-06
Novartis USD 3.24B 101M 2026-06
Novartis USD 3.14B 296M 2026-03
Novo Nordisk DKK 16.31B 3.09B 2026-06
Orion EUR 98.9M 7M 2026-06
Pfizer USD 3.41B 496M 2026-06
Philips EUR 1.21B 23M 2026-06
Recordati EUR 201.58M 8.82M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 307M 2026-06
UCB EUR 1.47B 193M 2025-12